Mito-metformin Neuroprotection via Mitochondrial Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases like Parkinson's do not effectively halt or slow disease progression and lack compounds that improve mitochondrial function, leading to significant neuronal cell death and degeneration.
Innovation Solution
Modified metformin compounds, such as mito-metformin, are administered to provide neuroprotection by targeting mitochondria, enhancing mitochondrial sequestration and bioavailability, activating AMPK-PKD1 signaling, and promoting mitochondrial biogenesis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If current treatments are used to manage neurodegenerative diseases, then motor symptoms can be alleviated by compensating for neurochemical deficits, but disease progression cannot be halted or slowed and neuronal cell death continues
Solution Approach 1:
The patent extracts the therapeutic action from symptomatic compensation to direct mitochondrial targeting. By modifying metformin with triphenylphosphonium groups, the compound is specifically directed to mitochondria where it can directly address the root cause of neurodegeneration (mitochondrial dysfunction) rather than merely compensating for downstream neurochemical deficits.
Solution Approach 2:
The triphenylphosphonium-modified metformin acts as an intermediary that bridges the gap between systemic administration and mitochondrial action. The modification enables the compound to cross cell membranes and selectively accumulate in mitochondria, serving as a mediator that delivers neuroprotective effects directly to the organelle level while being administered systemically.
2Adaptability or versatility
If mitochondrial function is not targeted, then general neurochemical compensation can be provided, but mitochondrial dysfunction and neuronal cell death continue to progress
Solution Approach 1:
The patent applies local quality by concentrating the therapeutic effect specifically at the mitochondrial level. The triphenylphosphonium modification causes the metformin derivative to accumulate preferentially in mitochondria, creating a high local concentration exactly where mitochondrial dysfunction occurs, rather than distributing the compound uniformly throughout the cell.
Solution Approach 2:
The patent changes the chemical parameters of metformin by adding triphenylphosphonium groups, which fundamentally alters its distribution properties. This parameter change enables selective mitochondrial accumulation through electrostatic interaction with the negatively charged mitochondrial inner membrane, transforming a non-specific compound into a targeted mitochondrial agent.
3Ease of manufacture
If standard metformin is used, then general metabolic effects are achieved, but mitochondrial sequestration and neuroprotective efficacy are insufficient
Solution Approach 1:
The patent creates a composite molecular structure by combining metformin with triphenylphosphonium groups. This composite molecule integrates the metabolic activity of metformin with the mitochondrial-targeting capability of triphenylphosphonium, achieving both general metabolic effects and concentrated mitochondrial action in a single compound.
Solution Approach 2:
The patent changes the lipophilicity and charge distribution parameters of metformin through triphenylphosphonium modification. This parameter change enables the compound to cross cell membranes efficiently and accumulate in mitochondria through electrostatic attraction to the negatively charged mitochondrial membrane, achieving high mitochondrial concentrations without requiring excessive dosing.
Data Source
AI summary
The present invention provides modified metformin compounds, particularly mito-metformin compounds, and pharmaceutical compositions thereof. Methods of using the compounds to provide neuroprotection and in the treatment and/or prevention of neurodegenerative diseases are also described.